Analysts expect that Hill-Rom Holdings, Inc. (NYSE:HRC) will report $719.38 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Hill-Rom’s earnings, with the highest sales estimate coming in at $722.30 million and the lowest estimate coming in at $718.20 million. Hill-Rom posted sales of $708.60 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 1.5%. The firm is expected to announce its next earnings report before the market opens on Friday, August 2nd.

According to Zacks, analysts expect that Hill-Rom will report full year sales of $2.90 billion for the current fiscal year, with estimates ranging from $2.89 billion to $2.90 billion. For the next fiscal year, analysts expect that the business will post sales of $2.98 billion, with estimates ranging from $2.91 billion to $3.02 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Hill-Rom.

Hill-Rom (NYSE:HRC) last issued its quarterly earnings data on Friday, April 26th. The medical technology company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $1.11 by $0.03. Hill-Rom had a net margin of 7.93% and a return on equity of 21.30%. The business had revenue of $714.20 million for the quarter, compared to analysts’ expectations of $705.59 million. During the same period in the previous year, the business earned $1.05 earnings per share. The company’s revenue was up .5% on a year-over-year basis.

Several equities research analysts have commented on the stock. Zacks Investment Research upgraded shares of HENKEL AG & CO/S from a “sell” rating to a “hold” rating in a research report on Thursday, June 6th. ValuEngine upgraded shares of China Southern Airlines from a “sell” rating to a “hold” rating in a research report on Tuesday, June 11th. Finally, Barclays boosted their price target on shares of Zimmer Biomet from $113.00 to $117.00 and gave the stock an “underweight” rating in a research report on Monday, April 15th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $107.00.

Hill-Rom stock traded up $0.36 during midday trading on Monday, hitting $106.98. The company’s stock had a trading volume of 202,715 shares, compared to its average volume of 293,146. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.69 and a quick ratio of 1.27. The business’s 50-day simple moving average is $104.95. Hill-Rom has a 12 month low of $81.82 and a 12 month high of $108.68. The firm has a market capitalization of $7.14 billion, a P/E ratio of 22.52, a PEG ratio of 1.84 and a beta of 0.92.

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Friday, September 20th will be given a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 0.79%. The ex-dividend date of this dividend is Thursday, September 19th. Hill-Rom’s dividend payout ratio (DPR) is presently 17.68%.

Institutional investors and hedge funds have recently modified their holdings of the stock. Hanseatic Management Services Inc. purchased a new position in Hill-Rom in the 1st quarter worth about $30,000. Sageworth Trust Co purchased a new position in Hill-Rom in the 1st quarter worth about $32,000. Financial Gravity Wealth Inc. purchased a new position in Hill-Rom in the 1st quarter worth about $53,000. Osborn Williams & Donohoe LLC purchased a new position in Hill-Rom in the 1st quarter worth about $53,000. Finally, Bay Harbor Wealth Management LLC increased its stake in Hill-Rom by 78.9% in the 2nd quarter. Bay Harbor Wealth Management LLC now owns 535 shares of the medical technology company’s stock worth $56,000 after purchasing an additional 236 shares in the last quarter. 81.38% of the stock is currently owned by hedge funds and other institutional investors.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Recommended Story: What is the formula for calculating total return?

Get a free copy of the Zacks research report on Hill-Rom (HRC)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with's FREE daily email newsletter.